GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (STU:AX9) » Definitions » Cyclically Adjusted Price-to-FCF

Akebia Therapeutics (STU:AX9) Cyclically Adjusted Price-to-FCF : (As of May. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Akebia Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Akebia Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Cyclically Adjusted Price-to-FCF Chart

Akebia Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Akebia Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Akebia Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Akebia Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Akebia Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Akebia Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Akebia Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.087/131.7762*131.7762
=-0.087

Current CPI (Mar. 2024) = 131.7762.

Akebia Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.251 100.560 -0.329
201409 -0.222 100.428 -0.291
201412 -0.377 99.070 -0.501
201503 -0.394 99.621 -0.521
201506 -0.407 100.684 -0.533
201509 -0.283 100.392 -0.371
201512 -0.695 99.792 -0.918
201603 0.422 100.470 0.553
201606 -0.664 101.688 -0.860
201609 -0.694 101.861 -0.898
201612 2.368 101.863 3.063
201703 -0.240 102.862 -0.307
201706 0.528 103.349 0.673
201709 -0.987 104.136 -1.249
201712 -0.300 104.011 -0.380
201803 -0.344 105.290 -0.431
201806 0.133 106.317 0.165
201809 -0.192 106.507 -0.238
201812 -0.942 105.998 -1.171
201903 -1.057 107.251 -1.299
201906 -0.302 108.070 -0.368
201909 0.065 108.329 0.079
201912 -0.696 108.420 -0.846
202003 -0.631 108.902 -0.764
202006 0.241 108.767 0.292
202009 -0.161 109.815 -0.193
202012 -0.174 109.897 -0.209
202103 -0.387 111.754 -0.456
202106 -0.325 114.631 -0.374
202109 -0.275 115.734 -0.313
202112 -0.318 117.630 -0.356
202203 -0.110 121.301 -0.119
202206 -0.152 125.017 -0.160
202209 0.186 125.227 0.196
202212 -0.281 125.222 -0.296
202303 -0.089 127.348 -0.092
202306 0.018 128.729 0.018
202309 -0.036 129.860 -0.037
202312 -0.011 129.419 -0.011
202403 -0.087 131.776 -0.087

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Akebia Therapeutics  (STU:AX9) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Akebia Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Akebia Therapeutics (STU:AX9) Business Description

Industry
Traded in Other Exchanges
Address
245 First Street, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Akebia Therapeutics (STU:AX9) Headlines

No Headlines